Company intelligence / Profile preview

Theracell Advanced Biotechnology

Ownership: Private
Development stage: Commercial

Overview

Theracell Advanced Biotechnology develops advanced cell and gene therapies targeting orthopedic, dermatological, nephrological conditions as well as oncology and chronic inflammatory/metabolic diseases. Its lead programs use mesenchymal stromal cells for bone/joint/tissue regeneration. The company has received significant grant funding from the Greek government and was designated a “Priority Investment of Strategic National Importance.” Clinical progress includes at least one ongoing trial since September 2019. The company operates primarily out of Greece with a focus on personalized medicine using ATMPs.

Therapeutic areas: Rheumatology
Modalities: Cell therapy (e.g., mesenchymal stromal cells)Gene therapyTissue engineered products
Industry: Biotech

Partnerships

National Hellenic Research Foundation (clinical collaboration)

Beyond the preview

Go deeper on Theracell Advanced Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Theracell Advanced Biotechnology.